Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients

References

• Pileri SA, Agostinelli C, Sabattini E, et al. Lymphoma classification: the quiet after the storm. Semin Diagn Pathol 2011;28:113–123.
   PubMed Web of Science ®Google Scholar
• Sehn LH. A decade of R-CHOP. Blood 2010;116:2000–2001.
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587–4594.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• d’Amore F, Brincker H, Christensen BE, et al. Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. Ann Oncol 1992;3:379–386.
   PubMed Web of Science ®Google Scholar
• Yee KW, Pater JL, Pho L, et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 2003;21:1618–1623.
   PubMed Web of Science ®Google Scholar
• Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004;22:4626–4631.
   PubMed Web of Science ®Google Scholar
• Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383–1389.
   PubMed Web of Science ®Google Scholar
• Mareschal S, Lanic H, Ruminy P, et al. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 2011;96:1888–1890.
   PubMed Web of Science ®Google Scholar
• Klapper W, Kreuz M, Kohler CW, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 2012;119:1882–1887.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Miura K, Hojo A, et al. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 2011;137:1079–1084.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460–468.
   PubMed Web of Science ®Google Scholar
• Lanic H, Kraut-Tauzia J, Modzelewski R, et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 2014;55:817–823.
   PubMed Web of Science ®Google Scholar
• Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710–1715.
   PubMed Web of Science ®Google Scholar
• Szczuraszek K, Mazur G, Jelen M, et al. Prognostic significance of Ki-67 antigen expression in non-Hodgkin's lymphomas. Anticancer Res 2008;28:1113–1118.
   PubMed Web of Science ®Google Scholar
• Grogan TM, Lippman SM, Spier CM, et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988;71:1157–1160.
   PubMed Web of Science ®Google Scholar
• Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994;83:1460–1466.
   PubMed Web of Science ®Google Scholar
• Sanchez E, Chacon I, Plaza MM, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998;16:1931–1939.
   PubMed Web of Science ®Google Scholar
• Broyde A, Boycov O, Strenov Y, et al. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol 2009;84:338–343.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Choi DR, Ahn HJ, et al. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. Eur J Haematol 2010;85:149–157.
   PubMed Web of Science ®Google Scholar
• Seki R, Okamura T, Koga H, et al. Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma. Am J Hematol 2003;73:230–235.
   PubMed Web of Science ®Google Scholar
• Llanos M, Alvarez-Arguelles H, Aleman R, et al. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol 2001;18:15–22.
   PubMed Web of Science ®Google Scholar
• Hall PA, Richards MA, Gregory WM, et al. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 1988;154:223–235.
   PubMed Web of Science ®Google Scholar
• Hasselblom S, Ridell B, Sigurdardottir M, et al. Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Leuk Lymphoma 2008;49: 1501–1509.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Lowry L, Smith P, Cunningham D, et al. Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy. J Geriatr Oncol 2013;4:134–140.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Meguro A, Ozaki K, Sato K, et al. Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leuk Lymphoma 2012;53:43–49.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275–282.
   PubMed Web of Science ®Google Scholar
• Grubeck-Loebenstein B. Changes in the aging immune system. Biologicals 1997;25:205–208.
   PubMed Web of Science ®Google Scholar
• Tamir A, Eisenbraun MD, Garcia GG, et al. Age-dependent alterations in the assembly of signal transduction complexes at the site of T cell/APC interaction. J Immunol 2000;165:1243–1251.
   PubMed Web of Science ®Google Scholar
• Effros RB. Replicative senescence of CD8 T cells: effect on human ageing. Exp Gerontol 2004;39:517–524.
   PubMed Web of Science ®Google Scholar
• Gravekamp C, Jahangir A. Is cancer vaccination feasible at older age? Exp Gerontol 2014;54:138–144.
   PubMed Web of Science ®Google Scholar
• Joudi FN, Smith BJ, O’Donnell MA, et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 2006;175:1634–1639; discussion 1639–1640.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011;25:1502–1509.
   PubMed Web of Science ®Google Scholar
• Keane C, Gill D, Vari F, et al. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Am J Hematol 2013;88:273–276.
   PubMed Web of Science ®Google Scholar
• Cai QC, Liao H, Lin SX, et al. High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol 2012;29:2317–2322.
   PubMed Web of Science ®Google Scholar
• Rajnai H, Heyning FH, Koens L, et al. The density of CD8 + T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone. Virchows Arch 2014;464:229–239.
   PubMed Web of Science ®Google Scholar
• Linderoth J, Eden P, Ehinger M, et al. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma. Br J Haematol 2008;141:423–432.
   PubMed Web of Science ®Google Scholar
• Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010;116:4916–4925.
   PubMed Web of Science ®Google Scholar
• Oschlies I, Klapper W, Zimmermann M, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 2006;107:4047–4052.
   PubMed Web of Science ®Google Scholar
• Naz E, Mirza T, Danish F. Clinicopathologic evaluation of subgroups of diffuse large B cell lymphoma by immunohistochemistry. Asian Pac J Cancer Prev 2011;12:3335–3339.
   PubMed Web of Science ®Google Scholar
• Liu YH, Xu FP, Zhuang HG, et al. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Pathol 2008;39:875–884.
   PubMed Web of Science ®Google Scholar
• Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78–84.
   PubMed Web of Science ®Google Scholar
• Li ZM, Huang JJ, Xia Y, et al. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. Eur J Haematol 2012;88:510–517.
   PubMed Web of Science ®Google Scholar